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Antimicrobial use in animals is known to contrib-
ute to the global burden of antimicrobial resistance. 
Therefore, it is critical to monitor antimicrobial sales 
for livestock and pets. Despite the availability of vet-
erinary antimicrobial sales data in most European 
countries, surveillance currently lacks consumption 
monitoring at the animal species level. In this study, 
alternative methods were investigated for stratify-
ing antimicrobial sales per species using Swiss data 
(2006−2013). Three approaches were considered: (i) 
Equal Distribution (ED) allocated antimicrobial sales 
evenly across all species each product was licensed 
for; (ii) Biomass Distribution (BMD) stratified antimi-
crobial consumption, weighting the representativeness 
of each species’ total biomass; and (iii) Longitudinal 
Study Extrapolation (LSE) assigned antimicrobial sales 
per species based on a field study describing prescrip-
tion patterns in Switzerland. LSE is expected to pro-
vide the best estimates because it relies on field data. 
Given the Swiss example, BMD appears to be a reli-
able method when prescription data are not available, 
whereas ED seems to underestimate consumption in 
species with larger populations and higher treatment 
intensity. These methods represent a valuable tool for 
improving the monitoring systems of veterinary anti-
microbial consumption across Europe.
Introduction
Antimicrobial resistance has been gaining momentum 
as one of the most important topics within the public 
health sphere [1]. Part of the antimicrobial resistance 
burden for public health lies on the use of antimicro-
bials for veterinary purposes. Results from several 
studies have suggested that antimicrobial exposure in 
livestock is contributing to the emergence, selection 
and spread of antimicrobial resistant bacteria [2-4]. In 
addition, it is known that the use of antimicrobials in 
pets influences the resistance patterns found in those 
animals [5]. The subsequent spread of resistant bacte-
ria from animals to humans can occur through multiple 
potential routes.
Monitoring systems in veterinary medicine can pro-
vide useful insights into temporal trends of antimi-
crobial consumption and ensure compliance with 
prudent usage practices, programmes or regulations. 
Furthermore, they can assist in identifying the most 
efficient interventions for optimising antimicrobial 
usage. When combined with antimicrobial resistance 
data, quantification of antimicrobial usage can be 
useful not only in identifying risk factors for the emer-
gence of resistance, but also in describing temporal 
associations between antimicrobial usage and resist-
ance [6,7]. Finally, monitoring systems can be a source 
of highly informative data for boosting research on the 
complex topic of emergence, selection and spread of 
antimicrobial resistance. Thus, monitoring antimicro-
bial consumption in livestock and companion animals 
is undoubtedly an important tool in the battle against 
antimicrobial resistance.
Research on the veterinary use of antimicrobials has 
focused on livestock species because their popula-
tions are larger and their antimicrobial consumption 
is higher than that of pet animals. Recognition of the 
importance of quantifying antimicrobial use in live-
stock emerged more than a decade ago [8] and the 
European Commission and the European Medicines 
Agency (EMA) have also emphasised the importance of 
monitoring antimicrobial use [9-11]. There is no bind-
ing European Union (EU) legislation with respect to 
the implementation of such monitoring programmes at 
national level and it is up to each country to define its 
strategy. 
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In Switzerland, a non-EU country, the legal basis for 
sales data collection was defined in Article 35 of the 
Federal Ordinance on Veterinary Medicinal Products, 
enacted in September 2004 [12].
The European Surveillance of Veterinary Antimicrobial 
Consumption (ESVAC) project, initiated in 2010 by the 
EMA, has contributed considerably to the collection 
of standardised data on veterinary consumption in 
Europe [13]. ESVAC reports are published annually and 
are currently based on data provided by 26 countries, 
including Switzerland [14].
Prompted by the European Commission’s Action plan 
against the rising threats from Antimicrobial Resistance 
[10], ESVAC published guidance for data collection 
on antimicrobial consumption at the species level 
[15]. Furthermore, international guidelines such as 
the World Organisation for Animal Health’s Terrestrial 
Animal Health Code [7] and Integrated Surveillance 
of Antimicrobial Resistance: Guidance from a WHO 
Advisory Group [16], mention usage data at the species 
level as an important aspect that should be considered 
in monitoring systems. Data at the species and the pro-
duction type level (such as dairy or beef cattle; broilers 
or laying hens; breeding, farrowing or fattening units) 
provide a better estimate of the antimicrobial expo-
sure in each population and are therefore much more 
informative than overall sales data.
In mid-2000, Denmark implemented an automated sys-
tem for nationwide collection of antimicrobial prescrip-
tion data for production animals (pigs, poultry, cattle, 
sheep, goats, fish and mink) [6]. Systems providing 
data at the farm level can be used to identify high 
consumers and therefore implement benchmarking 
systems based on usage by individual farms or prac-
titioners [17-19]. However, such systems can be very 
demanding in terms of resources and infrastructure 
[16] which might hinder their establishment.
In the absence of automated data collection schemes, 
alternatives need to be explored. ESVAC suggests that 
estimates of antimicrobial usage per species can be 
obtained through cross-sectional or longitudinal stud-
ies or based on data from marketing authorisation 
holders [15]. Some of these strategies have already 
been applied. In the Netherlands, longitudinal data 
on antimicrobial usage were collected from a sample 
of farms [20]. In France, antimicrobial consumption 
per animal species has been calculated based on esti-
mates of marketing authorisation holders since 2009 
[21].
In Switzerland, antimicrobial sales data have been 
obtained yearly at national level since 2004 by request-
ing the number of packages sold per product from the 
marketing authorisation holders [22]. However, this 
strategy does not enable quantification of antimicro-
bial consumption at the species level.
There is no standardised method for quantifying the 
distribution of antimicrobial sales per animal species. 
The choice of the method also depends on data avail-
ability. It is therefore of interest to compare different 
possible methods and observe how results vary.
The aim of this study was to propose and compare 
alternative methods for estimating the antimicrobial 
consumption in pet and livestock animal species or 
groups of species in Switzerland by combining sales 
data with (i) summary of product characteristics; (ii) 
summary of product characteristics and animal demo-
graphic data; (iii) prescription data from a longitudinal 
study.
Methods
Antimicrobial sales data and product 
information
Based on information obtained from marketing author-
isation holders, the number of antimicrobial packages 
sold per product is converted into the corresponding 
amount of active ingredient. The results are published 
in the ARCH-Vet report (the official annual report on 
sales of antibiotics in veterinary medicine and antibi-
otic resistance monitoring of livestock in Switzerland) 
by the Federal Food Safety and Veterinary Office (FSVO) 
[23].
The FSVO granted the authors access to the detailed 
antimicrobial sales database. The models developed 
in this study were fed with sales data from the period 
2006−2013. Results from these models are a proxy for 
antimicrobial consumption.
Antimicrobial products were categorised into two 
groups: monospecies products (authorised for a single 
species) and multispecies products (licensed for multi-
ple species). This stratification was done by extracting 
from the Swiss Veterinary Drug Compendium data on 
the species each product is licensed for [24]. The fol-
lowing species or groups of related species (hereafter 
referred to as ‘species’) were considered: pigs, cattle, 
poultry, small ruminants (goats and sheep grouped 
together), horses and pets (cats and dogs grouped 
together). Poultry is roughly equivalent to the number 
of chickens because turkey or waterfowl production in 
Switzerland is negligible. It should also be noted that, 
in Switzerland, most horses are kept for leisure and 
only a small number enter the food chain.
Rabbits and fish were excluded as their population sizes 
are comparatively small, and therefore these groups 
are expected to represent a negligible contribution to 
the consumption of antimicrobials in Switzerland.
Animal demographic data
The national total biomass of each species was cal-
culated from 2006 to 2013 using the population cor-
rection unit (PCU) method. PCU is a technical unit 
of measurement. One PCU is equivalent to 1  kg of 
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biomass of livestock and slaughtered animals [13]. For 
livestock, theoretical weights at the most likely time for 
treatment were based on ESVAC recommendations [15]. 
For cats and dogs we used 5 kg and 20 kg bodyweight, 
respectively, as these are accepted standards for drug 
regulatory agencies [25].
When possible, sources of demographic data used for 
the ESVAC report were consulted [26]. For pets, demo-
graphic data were collected from the Société pour 
l’alimentation des animaux familiers (Swiss Society for 
Pet Nutrition) [27,28]. For the years where no data were 
available (2009, 2011, 2013), the mean of the previous 
and the following year was used.
Field data on antimicrobial prescription 
patterns
Regula et al. (2009) assessed the prescription pat-
terns of veterinarians in Switzerland for the period 
2004−2005 [29]. Eight veterinary practices, represent-
ing 1.5% of all veterinary clinics in Switzerland (with a 
total of 15 veterinarians), were selected based on the 
proportion of owners keeping livestock and the use 
of electronic databases for disease and prescription 
records. Cattle, pigs, sheep, goats, horses, dogs and 
cats were included in this study. The proportion of ani-
mals at risk of being treated in the field study relative to 
the total number of animals in the country varied across 
the different animal species. To take this into account, 
the total amount of active ingredient prescribed was 
divided by the percentage of animals of each species 
at risk of being treated. The number of animals at risk 
of being treated during the field study were calculated 
as follows: (i) for horses, the number of owners in the 
practice records was used as a proxy for the number 
of animals (ii) for pets, the number of owners in the 
practice records was multiplied by the mean number of 
pets per household in Switzerland [27,28]; (iii) for pigs 
and cattle, veterinarians enrolled in the study provided 
estimates of the number of animals on the farms they 
visited; (iv) the number of small ruminants at risk of 
being treated was calculated based on the number of 
cattle at risk of being treated. We assumed that the 
ratio of cattle to small ruminants in the field study was 
the same as at the national level [26].
Field data were used to estimate the distribution of 
antimicrobial consumption by different species. These 
estimates were used to calculate mode values of 
Program Evaluation and Review Technique (PERT) dis-
tributions used in the Longitudinal Study Extrapolation 
(LSE) model described in detail below.
Distribution of antimicrobial sales per species
Three different methods were used to extrapolate anti-
microbial usage per species from sales data: Equal 
Distribution (ED), Biomass Distribution (BMD) and 
Longitudinal Study Extrapolation (LSE). Each method 
was exemplified using Swiss data, allowing for the 
calculation of estimates of antimicrobial consumption 
for several animal species from 2006 to 2013. Data 
analyses were performed using R statistical software 
[30].
Consumption estimates are presented in mg per PCU 
when referring to total national consumption and in mg 
per kg of biomass when describing the consumption by 
specific animal species.
Equal Distribution 
ED assumed that antimicrobial consumption was equal 
for each species a product was licensed for. Thus, the 
amount of antimicrobial product used by a species in a 
given year was calculated as follows: 
C: Consumption estimate; pa: a given product; ya: a 
given year; speca: a given species for which a product 
is licensed; specn: all the species for which a product 
is licensed; S: amount of product in sales.
The model was developed on a product basis. 
Calculated amounts of active ingredient belonging to 
the same antimicrobial class were summed for each 
year and animal species.
Biomass Distribution 
In this method, the amount of product sold (in 
2006−2013) was distributed proportionally to the 
relative importance of a species’ total biomass at a 
national level. The analysis was done for each product 
individually, taking into account the animal species the 
product is licensed for and the corresponding annual 
biomass values. The calculation for every product was 
performed as follows: 
C: Consumption estimate; pa: a given product; ya: a 
given year; speca: a given species a product is licensed 
for; specn: all the species a product is licensed for; S: 
amount of product in sales; BM: biomass.
Finally, the results were summed up for every combina-
tion of animal species, antimicrobial class and year.
Longitudinal Study Extrapolation 
In this approach, estimates of the antimicrobial sales 
repartition per species (i.e. the amount of antimicro-
bials sold for use by each species) were derived from 
a Monte Carlo simulation, using PERT distributions to 
model the uncertainty of the data derived from the lon-
gitudinal study. This type of beta distribution is gen-
erated from three values: minimum (Min), mode and 
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maximum (Max). PERT distributions were created for 
every combination of antimicrobial class, year and ani-
mal species. The values in these distributions ranged 
from 0 to 1 and represented proportions of the total 
amount of sales for the respective antimicrobial class 
in a given year.
Min and Max were calculated by combining sales 
data with information from the Swiss Veterinary Drug 
Compendium [24]. Min was estimated by summing the 
amounts of monospecies products sold for each com-
bination of antimicrobial class, animal species and 
year. Max was calculated as the sum of the amounts 
sold of all the products (monospecies and multispecies 
products) of a certain antimicrobial class licensed for a 
specific species, in a specific year.
Both Min and Max values were converted into a propor-
tion of the total amount of antimicrobial for the same 
combination of antimicrobial class and year. In sum-
mary, Min and Max were calculated as follows:
Min: minimum of the PERT distribution; Max: maximum 
of the PERT distribution; Mono: monospecies products; 
Multi: multispecies products; speca: a given species a 
product is licensed for; ya: a given year; AMCa: a given 
antimicrobial class; S: amount of product in sales.
Mode values of the PERT distributions were based on 
data from the field study on antimicrobial prescrip-
tion patterns in Switzerland [29]. Specifically, the total 
amount of active ingredient from each antimicrobial 
class prescribed for each species was divided by the 
total amount of authorised products for that same spe-
cies and antimicrobial class. This value was then used 
to estimate a mode value between the Min and the 
Max. The mode for each combination of species, anti-
microbial class and year was calculated as follows:
Mode: mode of the PERT distribution; F: amount of anti-
microbial from the field study; Min: minimum of the 
PERT distribution; Max: maximum of the PERT distribu-
tion; Mono: monospecies products; Multi: multispecies 
products; speca: a given species a product is licensed 
for; ya: a given year; AMCa: a given antimicrobial class; 
specn:: all the species a product is licensed for.
Poultry was not included in the field study, and there-
fore mode values for the PERT distributions of this spe-
cies group were calculated as the mean value of the 
Min and Max for each year.
The mode values were standardised so that they added 
up to 1 for each combination of antimicrobial class and 
year. For this, the mode values were recalculated pro-
portionally to their species distribution in the longitu-
dinal study.
The simulation model was then run 10,000 times, 
using the R package ‘mc2d’ [31], and the mean of the 
results of each iteration was calculated. This result 
represented the proportion of the total sales of a cer-
tain antimicrobial class in a given year that was sold 
for consumption by a given animal species. Due to the 
stochasticity of the model and the skewness of some 
distributions (particularly when the mode value was 
close to the Min or Max), the sum of the repartition per 
species was often different from 100% for each year/
antimicrobial class combination. For that reason, the 
repartition values were standardised proportionally to 
each species estimates. The 95% credibility intervals 
for each estimate were calculated using the R package 
‘stats’ [30]. Finally, these values were used to estimate, 
for each antimicrobial class and year, the amount of 
antibiotics sold for use by each of the animal species.
For the three models, results are presented at an anti-
microbial class level as the total amount of antimicrobi-
als sold in kg and as mg of active ingredient sold per 
kg biomass.
Due to confidentiality reasons, no results disclosing the 
sales of individual products or marketing authorisation 
holders can be presented. Thus, sales at an antimicro-
bial class level are not shown for some species.
Results
Descriptive statistics: veterinary antimicrobial 
sales data from Switzerland, 2006–2013
From 2006 to 2008 there was an increase in the sale 
of veterinary antimicrobial products from 67,423  kg 
of active ingredient to 72,300 kg. Starting in 2008, a 
steady decrease in sales was observed, resulting in a 
total reduction of 26.2% by 2013.
The amount of monospecies products sold throughout 
the study period ranged from 24.9% (2011) to 30.1% 
(2006) of the total amount of antimicrobial product 
sold. Multispecies products authorised for two species 
represented 51.6–56.4% of the total amount of antimi-
crobial sold in each of the 8 years considered.
When the total sales were converted into mg per PCU, it 
was observed that variations in animal demographics 
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did not influence the antimicrobial consumption pat-
tern. Sales per PCU peaked in 2008 (87.9 mg/PCU); 
in 2013, the sale of veterinary antimicrobial products 
reached a minimum of 64.5 mg/PCU (Table 1).
PCU: population correction unit.
‘Others’ includes amphenicols, quinolones (other than 
fluoroquinolones), lincosamides, pleuromutilins
Sulfonamides, tetracyclines and penicillins were the 
antimicrobial classes sold the most throughout the 
years. Their contribution to the total sales ranged from 
81.7% to 82.3% of the total mg per PCU. In parallel, 
sulfonamides and tetracyclines were the antimicrobial 
classes that contributed most to the observed decrease 
in antimicrobial consumption from 2008 to 2013, with 
decreases of 12.5 and 6.3 mg per PCU, respectively.
Equal Distribution
ED estimated that most of the antimicrobials (min−max, 
2006−2013) were sold for use in pigs (42.6−46.4%) 
and cattle (41.4−44.1%). Over the years, a decrease 
in the sale of antimicrobials for pigs was observed. 
However, the proportion of antimicrobials sold for cat-
tle increased, despite a reduction in the total amount 
of antimicrobials sold for this species (Figure 1).
The estimates for poultry revealed a negligible contri-
bution to the overall sales (0.9−1.1%).
When using mg of antimicrobial per kg biomass (mg/
BM) as a consumption metric, pets (145.4−179.5 mg/
BM) and pigs (110.0−160.0 mg/BM) were the species 
that seemed to be under the greatest antimicrobial 
pressure. Antimicrobials for cattle ranged from 48.8 to 
64.5 mg/BM (Table 2).
Biomass Distribution 
Estimates from this model highlighted cattle as the 
species for which most antimicrobials were sold, with 
an increase in percentage from 57.6% in 2006 to 62.7% 
in 2013. Despite this result, the total amount of anti-
microbials sold for cattle decreased from 38,809 kg to 
33,446 kg in the same period. For pigs, percentages 
ranged from 38.7% in 2006 to 33.1% in 2013. For other 
species, the repartition estimates varied as follows: 
pets 1.7−1.9%; small ruminants 0.8−0.9%; horses 
0.8−0.9%; poultry 0.3−0.9%.
Using mg/BM as a consumption metric, the values 
for the three main livestock species were between 
86.3−124.4 mg/BM for swine, 69.3−90.9 mg/BM for 
cattle and 4.3−6.2 mg/BM for poultry (Table 2).
Longitudinal Study Extrapolation 
With the exception of small ruminants (for which 
antimicrobial sales were relatively stable through-
out the years), the LSE model calculated a reduction 
in antimicrobial consumption over time for all spe-
cies. Total consumption of antimicrobials by cattle as 
Figure 1
Distribution of total antimicrobial sales per species according to the three different approaches. Switzerland, 2006–2013
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a percentage of consumption by all species was low-
est in 2006, at 57.6% (33.2−72.8%) (mean (minimum 
of the 95% credibility interval–maximum of the 95% 
credibility interval)) and highest in 2012, at 61.8% 
(35.7−78.3%). The consumption of antimicrobials by 
pigs went in the opposite direction, with a minimum of 
28.8% (12.4−55.1%) in 2012 and a maximum of 33.4% 
(17.9−58.1%) in 2006.
Despite some differences in terms of the relative 
proportion of consumption of different antimicro-
bial classes (Figure 2), estimates for pigs and cattle 
decreased over time in terms of mg/BM: the estimated 
consumption by cattle dropped from 81.6 mg/BM 
(47.1−103.3 mg/BM) in 2006 to 67.4 mg/BM (38.7−85.4 
mg/BM) in 2013; for pigs, consumption estimates went 
down from 102.5 mg/BM (54.9−178.6 mg/BM) to 76.4 
mg/BM (34.0−143.8 mg/BM) in the same time period.
For cattle, sulfonamides were the antimicrobial class 
that contributed the most to this decrease; for pigs, 
tetracyclines and sulfonamides were the classes for 
which consumption reduced the most (Figure 3).
Discussion
We compared different methods for stratifying antimi-
crobial sales data per animal species in Switzerland. 
This research follows the premise of the ESVAC project 
regarding the need to develop quantification methods 
of antimicrobial consumption at the species level [15].
The observed decrease of 26.2% in antimicrobial sales 
from 2008 to 2013 is most likely related to several con-
comitant reasons. Increased awareness by farmers and 
veterinarians about the issue of antimicrobial usage 
and resistance, due to several educational programmes 
by the FSVO, including the StAR programme [32], might 
have played a role in this decline. Viral diseases can 
lead to the use of antimicrobials to treat secondary 
infections [33,34]. For this reason, the implementation 
of the Bovine Viral Diarrhoea eradication programme 
and the commercialisation of Porcine Circovirus-2 vac-
cines might also have contributed to this reduction.
With regards to the results of the models, ED seemed 
to overestimate antimicrobial consumption for all spe-
cies except cattle. ED does not consider variation in the 
levels of consumption by different species and does 
not take into account animal demographics, which 
might explain this overestimation. Indeed, it is likely 
Figure 2
Relative distribution of the consumption of different antimicrobial classes for pigs and cattle, Switzerland, 2006–2013
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that differences exist in the species repartition for mul-
tispecies products, especially in those shared between 
livestock and pet animals. Moreover, in Switzerland, 
the total cattle biomass was higher than for other spe-
cies [35], largely due to the large number of dairy cat-
tle. Given that this method did not take into account 
the existing number of animals in the country, it proba-
bly underestimated the usage for species with a higher 
total biomass and overestimated the usage for species 
with a lower total biomass.
The differences in the species total biomass values 
substantially influenced the BMD estimates, as bio-
mass is the main driver for the repartition of sales data 
when using this approach. It was therefore not surpris-
ing that estimates of antimicrobial consumption by 
cattle were higher than those from ED. Concomitantly, 
extrapolated consumption by species with a lower bio-
mass but high treatment intensity might have been 
underestimated.
For cattle and pigs, estimates from BMD and LSE were 
similar throughout the study period. The maximum dif-
ference between the two approaches was 16.2 mg/
BM for pigs and 1.9 mg/BM for cattle. For the other 
species, LSE estimates tended to lie between ED and 
BMD results. The BMD approach seems to be a useful 
method when field data are not available. Nevertheless, 
extrapolation of this method to other countries should 
be done with care, as it is highly dependent on animal 
demographics.
The LSE method calculated a steady decrease in antimi-
crobial consumption throughout the studied years for 
most of the species. Small ruminants were an excep-
tion and were associated with a minor increase over 
the study period, from 44.9 mg/BM (2.1−130.5 mg/
BM) to 45.9 mg/BM (2.0−133.7 mg/BM). Nevertheless, 
it should be highlighted that the uncertainty around 
these estimates is large.
In poultry, a steep decrease in the estimates of antimi-
crobial consumption (from 21.0 mg/BM (6.9 − 34.9 mg/
Figure 3
Estimated antimicrobial consumption of different antimicrobial classes for pigs and cattle, Switzerland, 2006–2013
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BM) to 13.9 mg/BM (4.8 − 22.6 mg/BM)) was observed 
from 2006 to 2007. This change might be a model arte-
fact and not a true reduction in antimicrobial consump-
tion. As field data were unavailable for poultry, mode 
values of PERT distributions might not have been very 
accurate, especially for those antimicrobial classes 
where the difference between the Min and the Max was 
more accentuated. In those cases, it is likely that the 
mode used to represent poultry’s antimicrobial con-
sumption was overestimated. In addition, this steep 
decrease might be partly related to the discontinuation 
of some products licensed for poultry between 2006 
and 2008.
Pigs showed the largest decrease in antimicrobial con-
sumption. We estimated that the pig producing indus-
try had a particularly large antimicrobial consumption 
in the beginning of the study, and thus more opportuni-
ties to reduce usage were available, which might par-
tially explain this steep decrease. Furthermore, the use 
of vaccines against Porcine Circovirus-2 and porcine 
proliferative enteritis (Lawsonia intracellularis) might 
also have played a role in the reduction of antimicro-
bial sales for use in pigs.
The wide use of Porcine Circovirus-2 vaccination in 
Switzerland might be associated with a lower preva-
lence of respiratory disease [36]. Tetracyclines are the 
main class used to treat respiratory disease in pigs 
[37]. We investigated whether LSE was able to capture 
this decline in specific antimicrobial classes. Indeed, 
tetracycline consumption showed a decline by 38.0% 
in pigs (larger than the decline for any other species) 
between 2008 and 2013.
On an antimicrobial class level, differences were 
observed between the classes used to treat pigs and 
cattle. Despite the general decrease in the usage of 
most antimicrobial classes, a slight increase in the 
consumption of cephalosporins and fluoroquinolones 
was estimated for cattle and pigs.
One of the most relevant benefits of having antimi-
crobial consumption estimates at the species level 
relates to the possibility of analysing them together 
with the resistance patterns from the national monitor-
ing system. In Switzerland, indicator (Escherichiacoli 
and Enterococcus spp.) and zoonotic (Salmonella 
spp. and Campylobacter spp.) isolates from the three 
main livestock species (cattle, pigs and poultry) are 
collected every year. Regarding zoonotic bacteria, 
a general decrease in resistance was observed in 
Salmonella throughout the study period. This is in 
line with the reduction in antimicrobial consumption 
in the same period. For Campylobacter jejuni collected 
from poultry, a rise in the prevalence of ciprofloxacin 
resistant isolates was observed, from 12.0% in 2006 
to 41.4% in 2013. In the same period, an increase in 
the consumption of fluoroquinolones was observed. 
This is of particular relevance for public health given 
that fluoroquinolones are the treatment of choice for 
severe Campylobacter infections. With respect to 
Campylobacter coli from pigs, a fairly stable level of 
resistant isolates was found [38]; the level of anti-
microbial consumption did not seem to influence the 
resistance pattern observed.
Concerning the indicator bacteria, it is interesting to 
note that an increase of ciprofloxacin-resistant E.coli 
isolates was observed for poultry, which was more pro-
nounced than that for other species. On the other hand, 
streptomycin resistance in E. coli was higher for cattle 
and pigs when compared with broilers. This might be 
related to the lack of licensed aminoglycoside products 
for use in Swiss poultry production [38].
It is important to highlight that when assessing tempo-
ral associations between antimicrobial usage data and 
resistance, other factors need to be taken into account, 
such as cross- and co-resistance, as well as the emer-
gence and selection of specific clones. A comprehen-
sive analysis of these temporal patterns and the effect 
Table 1
Sales (mg per population correction unit) for different antimicrobial classes in Switzerland, 2006–2013
Veterinary antimicrobial sales in mg per PCU
2006 2007 2008 2009 2010 2011 2012 2013 
Aminoglycosides 4.6 4.6 4.5 4.3 3.9 4.0 3.9 3.8
Cephalosporins 0.6 0.6 0.6 0.7 0.7 0.7 0.7 0.6
Fluoroquinolones 0.4 0.5 0.5 0.5 0.5 0.5 0.4 0.5
Macrolides 4.4 4.9 5.2 4.9 4.6 4.2 4.0 3.8
Penicillins 15.9 15.9 16.6 15.8 16.1 16.4 15.9 15.8
Polymyxins 2.3 2.0 1.9 1.9 1.8 1.7 1.3 1.0
Sulfonamides/trimethroprim 35.8 38.2 37.7 35.1 32.9 29.6 27.6 24.3
Tetracycline 18.5 20.5 20.3 18.8 17.7 16.5 14.5 14.1
Others 0.4 0.6 0.5 0.5 0.5 0.9 0.7 0.7
Total 82.9 87.8 87.9 82.5 78.6 74.5 68.7 64.5
9www.eurosurveillance.org
Ta
bl
e 
2
A
nt
im
ic
ro
bi
al
 c
on
su
m
pt
io
n 
(m
g 
pe
r k
g 
of
 b
io
m
as
s) 
fo
r d
iff
er
en
t a
ni
m
al
 sp
ec
ie
s a
cc
or
di
ng
 to
 th
e 
th
re
e 
ap
pr
oa
ch
es
 in
 S
w
itz
er
la
nd
, 2
00
6–
20
13
An
tim
ic
ro
bi
al
 c
on
su
m
pt
io
n 
in
 m
g 
pe
r k
g 
of
 b
io
m
as
s
Ye
ar
Pi
gs
Po
ul
tr
y
Ca
tt
le
Sm
al
l r
um
in
an
ts
Ho
rs
es
Pe
ts
  E
D 
 
BM
D
  L
SE
  
ED
BM
D
LS
E
ED
BM
D
LS
E
ED
BM
D
LS
E
ED
BM
D
LS
E
ED
BM
D
LS
E
20
06
14
2.
6
11
8.
7
10
2.
5 
(5
4.
9−
17
8.
6)
20
.7
6.
2
21
.0
 
(6
.9
−3
4.
9)
58
.7
81
.6
81
.6
 
(4
7.
1−
10
3.
3)
69
.6
14
.1
44
.9
 
(2
.1
−1
30
.5
)
70
.6
25
.5
48
.4
 
(1
5.
7−
11
6.
0)
17
8.
1
68
.7
14
2.
1 
(5
8.
7−
30
0.
7)
20
07
15
3.
6
12
4.
6
10
9.
1 
(5
6.
7−
19
2.
3)
13
.4
5.
1
13
.9
 
(4
.8
−2
2.
6)
64
.2
89
.1
89
.1
 
(5
1.
3−
11
3.
2)
72
.0
14
.4
45
.3
 
(2
.0
−1
33
.2
)
72
.8
27
.7
49
.3
 
(1
7.
0−
11
5.
8)
17
4.
6
70
.9
13
9.
0 
(5
9.
3−
29
1.
5)
20
08
16
0.
0
12
4.
4
11
1.
0 
(5
4.
0−
20
1.
3)
12
.6
5.
2
13
.9
 
(5
.0
−2
2.
6)
64
.5
90
.9
89
.4
 
(5
0.
8−
11
3.
7)
71
.4
14
.4
45
.9
 
(2
.2
−1
33
.9
)
66
.3
25
.8
47
.2
 
(1
6.
4−
11
0.
1)
17
9.
5
70
.8
14
5.
3 
(6
0.
9−
30
2.
5)
20
09
14
7.
5
11
5.
9
10
2.
3 
(4
9.
8−
18
6.
4)
12
.4
5.
1
12
.7
 
(4
.4
−2
0.
7)
60
.6
85
.2
84
.3
 
(4
8.
0−
10
7.
2)
70
.9
13
.8
44
.9
 
(2
.1
−1
30
.5
)
61
.9
21
.8
42
.9
 
(1
4.
3−
10
3.
1)
17
5.
1
70
.7
14
1.
9 
(6
0.
9−
29
4.
3)
20
10
13
5.
0
10
7.
1
91
.6
 (4
2.
1−
17
0.
2)
12
.6
5.
2
12
.8
 
(4
.5
−2
1.
2)
58
.7
81
.9
82
.2
 
(4
6.
0−
10
4.
7)
70
.4
13
.2
45
.4
 
(2
.1
−1
32
.5
)
60
.1
23
.2
40
.8
 
(1
5.
1−
94
.3
)
17
8.
0
69
.4
14
4.
9 
(6
1.
0−
30
4.
6)
20
11
12
4.
6
97
.8
84
.0
 (3
6.
6−
16
0.
3)
12
.9
5.
6
12
.2
 
(4
.3
−2
1.
3)
56
.8
79
.4
78
.7
 
(4
4.
7−
10
1.
0)
70
.6
13
.2
45
.0
 
(2
.1
−1
31
.7
)
62
.3
24
.2
49
.3
 
(2
4.
0−
10
2.
7)
16
8.
0
67
.0
13
7.
3 
(5
9.
2−
28
1.
7)
20
12
11
5.
9
90
.3
78
.0
 (3
3.
7−
14
9.
4)
10
.1
4.
6
9.
0 
(3
.2
−1
5.
4)
52
.3
73
.9
72
.9
 
(4
2.
2−
92
.4
)
72
.4
13
.4
46
.5
 
(2
.1
−1
34
.6
)
60
.5
22
.5
40
.5
 
(1
3.
3−
97
.3
)
15
6.
9
60
.6
12
6.
7 
(5
2.
6−
26
3.
9)
20
13
11
1.
0
86
.3
76
.4
 (3
4.
0−
14
3.
8)
8.
8
4.
3
8.
2 
(2
.8
−1
4.
3)
48
.8
69
.3
67
.4
 
(3
8.
7−
85
.4
)
71
.9
13
.3
45
.9
 
(2
.0
−1
33
.7
)
54
.3
19
.6
36
.6
 
(1
0.
9−
90
.5
)
14
5.
4
57
.3
11
7.
3 
(4
7.
1−
24
8.
0)
BM
D:
 b
io
m
as
s 
di
st
rib
ut
io
n;
 E
D:
 e
qu
al
 d
is
tr
ib
ut
io
n;
 L
SE
: l
on
gi
tu
di
na
l s
tu
dy
 e
xt
ra
po
la
tio
n
Re
su
lts
 fo
r t
he
 th
re
e 
ap
pr
oa
ch
es
: 
ED
: e
qu
al
 s
al
es
 re
pa
rt
iti
on
 b
y 
th
e 
sp
ec
ie
s 
th
e 
pr
od
uc
ts
 a
re
 li
ce
ns
ed
 fo
r.
BM
D:
 s
al
es
 re
pa
rt
iti
on
 b
as
ed
 o
n 
th
e 
re
la
tiv
e 
to
ta
l b
io
m
as
s 
of
 th
e 
sp
ec
ie
s 
in
 th
e 
co
un
tr
y.
LS
E:
 s
al
es
 re
pa
rt
iti
on
 b
as
ed
 o
n 
re
su
lts
 fr
om
 a
 p
re
vi
ou
s 
fie
ld
 s
tu
dy
) p
re
se
nt
ed
 in
 m
g 
pe
r k
g 
bi
om
as
s.
 R
es
ul
ts
 fr
om
 L
SE
 a
re
 p
re
se
nt
ed
 a
s:
 m
ea
n 
(m
in
im
um
 9
5%
 c
re
di
bi
lit
y 
in
te
rv
al
 –
 m
ax
im
um
 9
5%
 c
re
di
bi
lit
y 
in
te
rv
al
). 
Go
at
s 
an
d 
sh
ee
p 
w
er
e 
gr
ou
pe
d 
to
ge
th
er
 a
s 
‘s
m
al
l r
um
in
an
ts
’; 
ca
ts
 a
nd
 d
og
s 
w
er
e 
gr
ou
pe
d 
to
ge
th
er
 a
s 
‘p
et
s’
. T
he
 s
pe
ci
es
 ‘h
or
se
s’
 is
 m
ai
nl
y 
re
pr
es
en
te
d 
by
 le
is
ur
e 
an
im
al
s
10 www.eurosurveillance.org
of antimicrobial consumption on the resistance of ani-
mal isolates should be performed.
Although it is not possible to validate the models, we 
are convinced that the LSE approach provided the best 
estimates. In this approach, input data for the model 
are derived from a longitudinal field study. These data 
are closer to the actual usage of antimicrobials than 
sales data and are therefore more likely to reflect 
reality. Nonetheless, the LSE method also presents 
some potential bias. In the first place, the field data 
that fed the model were from the period 2004−2005. 
Consumption patterns may have changed since then. 
However, product repartition values are not expected 
to vary greatly from year to year. In Switzerland, mar-
keting authorisation holders update their repartition 
estimates every 5 years. These estimates are used in 
the Periodic Safety Update Reports (PSURs) for calcu-
lating the incidence of adverse reactions. Nonetheless, 
we recommend performing field studies more fre-
quently when applying this method to yearly monitor-
ing. Another uncertainty might arise from the number 
of animals at risk of being treated in the field study, 
which was estimated from the participating veteri-
narians or calculated based on the number of farms/
owners. This may have introduced some bias into the 
extrapolation of the field study results to a national 
level. When applying this method, it is advisable to 
have accurate estimates of the number of animals at 
risk of being treated in the field study. In addition to 
the methods presented, data for antimicrobial sales 
repartition per species might be obtained by asking 
the marketing authorisation holders [21]. It has not 
yet been possible to apply this valuable approach in 
Switzerland due to data limitations. Likewise, reparti-
tion estimates from PSURs can also provide a basis for 
sales stratification.
We presented three methods for extrapolating anti-
microbial consumption per animal species from sales 
data. These approaches could be of use for countries 
which have not implemented detailed monitoring sys-
tems and which base their schemes on overall sales 
data. The best model choice in a given situation will 
depend on data availability. Results must always be 
interpreted in the light of data availability and country 
characteristics, and the limitations of each model must 
be considered. We shall also highlight that having con-
sumption data per species enables the calculation of 
treatment incidence metrics, which better describe 
exposure to antimicrobials than mg per PCU. The LSE 
approach might also be of relevance for monitoring sys-
tems that rely on compliance of the people prescribing 
and administering antimicrobials to animals. In cases 
of imperfect compliance, a model that repartitions total 
sales data per species allows comparison of recorded 
vs expected amounts used. This might be very useful 
for targeted interventions to improve data quality of 
the monitoring system.
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